Bionano Genomics, Inc: insider trades · United States · SEC (Form 4)

About Bionano Genomics, Inc

Bionano Genomics, Inc. is a U.S.-listed healthcare technology company trading on the NASDAQ market under the ticker BNGO in the United States. Originally incorporated as BioNano Genomics, the company adopted its current name in 2018 and is headquartered in San Diego, California, placing it within one of the most important life-science clusters in the United States. Bionano positions itself as a genome analysis solutions provider, with a focused strategy around optical genome mapping (OGM), a technology designed to identify structural variants in the genome that are often difficult to detect using conventional sequencing approaches. The company’s business model is built around three main pillars: OGM instruments, related consumables, and analytical software. Bionano markets its Saphyr and Stratys systems, which are designed to generate high-resolution genome mapping data for research and clinical use. These platforms are applied in areas such as hematologic malignancies, oncology research, constitutional genetic disorders, and selected cell and gene therapy workflows. In parallel, Bionano operates a services business through Bionano Laboratories, which provides OGM-based diagnostic testing services for clinicians and researchers who want access to the technology without purchasing and operating an instrument in-house. From a competitive standpoint, Bionano operates in a specialized but strategically important segment at the intersection of molecular diagnostics, clinical genomics, and advanced research tools. Its differentiation lies in its focus on structural variation, a category of genomic change where the company believes OGM can complement, and in some use cases outperform, legacy cytogenetic methods. The commercial opportunity is meaningful, but adoption depends on clinical validation, laboratory funding, and reimbursement dynamics. In that context, the recent establishment of a Category I CPT code for certain clinical OGM uses is an important step toward broader commercialization. Geographically, Bionano remains primarily anchored in the United States, while also expanding awareness and adoption internationally, including across Europe and Asia. Recent company updates highlight a growing installed base of OGM systems and an expanding group of routine users, which is important because recurring consumables and software usage support the business model. Key recent milestones include the launch and scaling of clinical OGM applications, the Bionano Symposium 2026, and multiple scientific presentations and publications supporting the platform’s relevance across hematologic malignancies, constitutional genetics, and bioprocessing. On the financing side, the company has also completed recent equity offerings, underscoring that liquidity and capital access remain central to execution. For investors, Bionano is a high-risk, high-optional value specialty medtech/genomics story with meaningful technology upside but continued execution and funding risk.